Page 1

Interim report 1 JANUARY - 31 MARCH 2021 Q1 An intensive start to 2021 First quarter : 1 January - 31 March 2021 Net sales amounted to SEK 0.0 million ( 0.2 ) . The operating result totalled SEK -63.8 million ( -55.9 ) . The result for the period amounted to SEK -63.2 million ( -56.0 ) . Earnings per share before and after dilution amounted to SEK -2.34 ( -2.44 ) . Cash flow from operating activities totalled SEK -56.1 million ( -59.1 ) . At 31 March 2021 , cash and cash equivalents totalled SEK 12.5 million ( 10.1 ) . Short - term investments in fixed - income funds amounted to SEK 106.1 million ( 165.7 ) , short - term components of listed corporate bonds to SEK 82.6 million ( 131.0 ) and long - term investments in listed corporate bonds to SEK 73.0 million ( 24.4 ) . • ● ● Q - LINEA Significant events in the first quarter of 2021 Q - linea received its first order for ASTar® from the Company's global sales partner Thermo Fisher Scientific , valued at over SEK 8 million . The order included a pre - payment for a binding order for the next six months . The Company contracted Thermo Fisher Scientific as the first site to participate in the Company's US clinical study for ASTar . Q - linea presented very good interim results from the pivotal European trial for antibiotic susceptibility system ASTar . after the end of the period Q - linea achieves CE - IVD approval for ASTar with very strong study results and can now commercialize ASTar in Europe together with its partner Thermo Fisher Scientific . Q - LINEA | INTERIM REPORT | Q1 2021 1